新しい診断と治療のABC79/血液9 悪性リンパ腫

出版社： 最新医学社
著者：
発行日： 2013-08-25
分野： 臨床医学：一般  >  雑誌
ISSN： 0370-824
電子書籍版： 2013-08-25
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

本誌では，悪性リンパ腫の概念，病理，診断を始め，ゆっくりとした診療で大丈夫なリンパ腫から，一刻を争い抗がん剤治療を急がなければならないリンパ腫まで，わかりやすく項目を分けて解説しております．専門医はもとより，専門医以外の方でも読みやすい内容にまとめました．悪性リンパ腫の成書として是非ご一読ください．

目次

  • 表紙
  • 監修
  • 序
  • MAP 眼で見る悪性リンパ腫
  • 目次
  • 執筆者
  • 第1章 概念・定義と疫学
  • 概念・定義
  • 疫学
  • 第2章 病理・病態生理
  • 病理
  • 病態生理
  • 病因
  • 第3章 診断
  • 診断
  • 検査所見
  • 画像診断
  • 鑑別診断
  • 1. 小腸リンパ腫
  • 2. 壊死性リンパ節炎
  • 第4章 管理・治療
  • HBVキャリア, 再活性化予防の管理
  • 悪心, 嘔吐などの有害事象の管理
  • 薬物療法・選択基準
  • 治療薬剤
  • 1. 濾胞性リンパ腫
  • 2. びまん性大細胞型B細胞リンパ腫
  • 3. T細胞リンパ腫
  • 4. NK細胞リンパ腫
  • リンパ系腫瘍に対する自家造血幹細胞移植
  • 同種造血幹細胞移植
  • 放射線療法
  • ピロリ菌除菌と胃MALTリンパ腫
  • 悪性リンパ腫の組織型からみた経過・晩期毒性を含めた予後
  • 医療経済
  • 第5章 ガイドライン
  • ガイドライン
  • 略語集
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.24 掲載の参考文献
1) Swerdlow S H, et al, eds:WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon:IARC Press;2008.
 
2) 中村栄男,他編:WHO 血液腫瘍分類～WHO 分類 2008 をうまく活用するために～. 医薬ジャーナル社,大阪, 2010.
 
3) 吉野正,他編:悪性リンパ腫臨床と病理-WHO分類(第4版) に基づいて-. 先端医学社,東京, 2009.
 
4) 岡本昌隆他:2000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度.-WHO分類第4版もふまえて-. 日リンパ網内会誌49:86, 2009.
 
5) Murase T, et al:Malignant-histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis:a report of five cases and review of the literature. Br J Haematol 99(3):656-664,1997.
 
6) Asano N, et al:Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 29 (10):1284-1293, 2005.
PubMed
7) Asano N, et al:Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma:a clinicopathologic study. J Clin Oncol 24 (28):4626-4633, 2006.
 
P.31 掲載の参考文献
1) Lymphoma Study Group of Japanese Pathogenesis:The World Health Organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50(9):696-702,2000.
 
2) A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood 89(11):3909-3918,1997.
 
3) Aozasa K, et al:Nation-wide study of lethal midline granuloma in Japan;frequencies of Wegener's granulomatosis, polymorphic reticulosis, malignant lymphomas and other related conditions. Int J Cancer 44:63-66, 1989.
 
4) Jarrett R F, et al:Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients of classic Hodgkin lymphoma:a population-based study. Blood 106:2444-2451, 2005.
PubMed
5) 中塚伸一,他:SV-40 ウイルスと悪性リンパ腫.血液腫瘍科 47:52-58, 2003.
 
6) Jaffe E S:Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis:from infection to translocation (Editorial). J Natl Cancer Inst 96:571-573, 2004.
PubMed
7) Niino D, et al:Regression of rectal mucosa-associated lymphoid tissue (MALT) lymphoma after antibiotic treatments. Pathol Int 60:438-442,2010.
PubMed
8) Thomas E, et al:Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497-500,2000.
PubMed
9) Wolfe F, et al:Lymphoma in rheumatoid arthritis:The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50:1740-1751,2004.
PubMed

第2章 病理・病態生理

P.48 掲載の参考文献
1) Jaffe E S, et al:Introduction and overview of the classification of the lymphoid neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissues. (Swerdlow S H, et al, eds), p158-166. IARC, Lyon,2008.
 
2) 鈴宮淳司:悪性リンパ腫. 臨床検査のガイドラインJSLM2012. 日本臨床検査医学会ガイドライン作成委員会編, p369-374. 宇宙堂八木書店, 東京, 2012.
 
3) Ichimura K, et al:Phenotypic analysis of peripheral T/NK cell lymphoma:study of 408 Japanese cases with special reference to their anatomical sites. Pathol Int 53(6):333-344,2003.
PubMed
4) 毛利博:上大静脈症候群・気道閉塞.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p272-275. 医薬ジャーナル社, 大阪, 2011.
 
5) Ponzoni M, et al:Definition, diagnosis, and management of intravascular large B-cell lymphoma:proposals and perspectives from an international consensus meeting. J Clin Oncol 25(21):3168-3173,2007.
 
6) 鵜飼知嵩,他:血管内大細胞型B細胞性リンパ腫の肺病変.血液内科 66(5):588-594, 2013.
 
7) 正木康史他:水腎症・閉塞性黄疸.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p276-282.医薬ジャーナル社, 大阪, 2011.
 
8) Hamano H, et al:High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344(10):732-738, 2001.
PubMed
9) Kumagawa M, et al:Splenic lymphoproliferative disorders in human T lymphotropic virus type-I endemic area of japan:clinicopathological, immunohistochemical and genetic analysis of 27 cases. Leuk Lymphoma 41(5-6):593-605,2001.
 
10) 山倉昌之,他:消化管穿孔.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p283-287.医薬ジャーナル社, 大阪, 2011.
 
11) Daum S, et al:Intestinal non-Hodgkin's lymphoma:a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 21(14):2740-2746,2003.
 
12) 秋山暢:中枢神経浸潤.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p254-271. 医薬ジャーナル社, 大阪, 2011.
 
13) Deckert M, et al:Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 25(12):1797-1807,2011.
PubMed
14) 安部正博:高カルシウム血症.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p288-293. 医薬ジャーナル社, 大阪 2011.
 
15) 高橋直人:血球貧食症候群.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p294-299. 医薬ジャーナル社, 大阪, 2011.
 
16) 尾畑由美子,他:悪性リンパ腫に伴う血球貧食症候群・病態と診断.血腫瘍 57 (supple 6):162-169, 2008.
 
17) Nakamura S, et al:Intravascular large B-cell lymphoma:the heterogeneous clinical manifestations of its classical and hemophagocytosis-related forms. Haematologica 92(4):434-436, 2007.
 
18) Kuriyama T, et al:Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood 120 (19):4058-4067, 2012.
 
19) 川内喜代隆:腫瘍崩壊症候群.みんなに役立つ悪性リンパ腫の基礎と臨床(改訂版) (押味和夫編), p300-307. 医薬ジャーナル社, 大阪, 2011.
 
20) Cairo M S, et al:TLS Expert Panel.:Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases:an expert TLS panel consensus. Br J Haematol 149 (4):578-586, 2010.
 
P.58 掲載の参考文献
1) Suarez F, et al:Infection-associated lymphomas derived from marginal zone B cells. A model of antigen-driven lymphoproliferation. Blood 107(8):3034-3044, 2006.
 
2) Bouvard V, et al:WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B:biological agents. Lancet Oncol 10(4):321-322, 2009.
 
3) IARC:A review of human carcinogens. Biological agent. IARC Monogr Eval Carcinog Risks Hum 100B:1-475, 2012. (http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php)
 
4) http://monographs.iarc.fr/ENG/Classiffication/index.php
 
5) Thorley-Lawson D A:EBV. The prototypical human tumor virus-just how bad is it? Allergy Clin Immunol 116(2):251-261, 2005.
PubMed
6) Thompson M P, et al:Epstein-Barr virus and cancer. Clin Cancer Res 10(3):803-821, 2004.
PubMed
7) Knowlton E R, et al:Professional antigen presenting cells in human herpesvirus 8 infection. Front Immunol 3:427-444, 2012.
PubMed
8) Pan Z G, et al:Extracavitary KSHV-associated large B-Cell lymphoma. A distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol 36(8):1129-1140, 2012.
PubMed
8) Stein H, et al:Plasmablastic lymphoma In:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th Ed (Swerdlow S H, et al, eds), p238-239. IARC Press, Lyon, 2008.
 
10) Lacroix A, et al:Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin's Lymphoma via DR7 Oncoprotein. Clin Cancer Res 16(19):4711-4721, 2010.
 
11) Marcucci F, et al:Hepatitis viruses and non-Hodgkin lymphoma. Epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 117(6):1792-1798, 2011.
PubMed
12) Vallisa D, et al:Role of antihepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma. A multicenter Italian experience. J Clin Oncol 23(3):468-473, 2005.
 
13) Kawamura Y, et al:Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120(12):1034-1041, 2007.
PubMed
14) Sugawara Y, et al:Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen-1. EMBO J 18(20):5755-5760, 1999.
PubMed
15) Nath A, et al:Prevalence of hepatitis B virus infection in non-Hodgkin's lymphoma. Asystematic review and meta-analysis. Intern Med J 40(9):633-641, 2010.
 
16) Du M Q, et al:Gastric MALT lymphoma. From aetiology to treatment. Lancet Oncol 3(2):97-104, 2002.
PubMed
17) Witkowska M, et al:Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm 2013 (Epub ahead of print)
 
18) Fukui T, et al:Immunogenetic analysis of gastrlc MALT-lymphoma-like lesions induced by Helicobacter pylori infection in neonatally thymectomized mice. Lab Invest 84(4):485-492, 2004.
PubMed

第3章 診断

P.68 掲載の参考文献
1) Longo D L, et al:Harrison's Principles of Internal Medicine 18th Ed. McGraw-Hill, New York, 2012.
 
2) Swerdlow S H, et al:World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 4th Ed. IARC Press, Lyon, 2008.
 
3) Weiss L:Lymph Nodes. Cambridge University Press, New York, 2008.
 
4) Murphy K, et al:Janeway's Immunobiology 7th Ed. Garland Science, New York and London, 2008.
 
P.79 掲載の参考文献
1) 一迫玲:細胞表面マーカー.日内会誌 97(7):1553-1560, 2008.
 
2) 畠 清彦,他:LYMPHOMA HANDBOOK 第4版, P8.中外製薬, 東京, 2009.
 
3) Soulas-Sprauel P, et al:V(D) J and immunoglobulin class switch recombinations:a paradigm to study the regulation of DNA end-joining. Oncogene 26(56):7780-7791, 2007.
 
4) Cleary M L, et al:Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Nat Acad Sci USA 81(2):593-597, 1984.
PubMed
5) Rosenwald A, et al:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937-1947, 2002.
PubMed
6) Hans C P, et al:Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275-282, 2004.
PubMed
P.89 掲載の参考文献
1) 日本アイソトープ協会医学・薬学部会サイクロトロン核医学利用専門委員会 FDG-PET ワーキンググループ,日本核医学会 PET 核医学委員会:PET検査件数に関するアンケート調査報告.第2報. Isotope News 2:30-31, 2005.
 
2) 立石宇貴秀:エキスパートによる PET/CT がん病期診断.秀潤社,東京, 2009.
 
3) Weiler-Sagie M, et al:18 F-FDG avidity in lymphoma readdressed:A study of 766 patients. J Nucl Med 51(1):25-30, 2010.
PubMed
4) Wirth A, et al:Impact of [(18)F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71(1):213-219, 2008.
 
5) Kostakoglu L, et al:FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107(11):2678-2687, 2006.
PubMed
6) Juweid M E, et al:Use of positron emission tomography for response assessment of lymphoma:consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25(5):571-578, 2007.
PubMed
7) Cheson B D, et al:Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579-586, 2007.
PubMed
8) Barrington S F, et al:Concordance between four European centres of PET reporting criteria designed for use in multicenter trials in Hodgkin lymphioma. Eur J Nucl Med Mol Imaging 37:1824-1833, 2010.
PubMed
9) Kapucu L O, et al:Fluorine-8-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 39:1267-1269, 1998.
 
10) Alavi A, et al:Positro emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 32:293-321, 2002.
 
11) Bakheet S M, et al:F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 25:273-278, 2000.
PubMed
12) 立石宇貴秀:悪性腫瘍診断のための PET/CT パーフェクトガイド.中山書店,東京, 2010.
 
P.97 掲載の参考文献
1) Mitsui K, et al:Role of double-balloon endoscopy in the diagnosis of small-bowel tumors:the first Japanese multicenter study. Gastrointest Endosc 70(3):498-504, 2009.
 
2) Nakamura S, et al:Primary gastrointestinal lymphoma in Japan:a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 97(10):2462-2473, 2003.
PubMed
3) Yamamoto H, et al:Clinical outcomes of double-balloon endoscopy for the diagnosis and treatment of small-intestinal diseases. Clin Gastroenterol Hepatol 2(11):1010-1016, 2004.
PubMed
4) Kobayashi H, et al:Clinical outcome of non-surgical treatment for primary small intestinal lymphoma diagnosed with double-balloon endoscopy. Leuk Lymphoma 54(4):731-736, 2013.
PubMed
5) 中村昌太郎,他:【癌や炎症と鑑別が困難な消化管悪性リンパ腫】癌や炎症と鑑別が困難な小腸悪性リンパ腫の臨床病理学的特徴 X 線・肉眼所見を中心に.胃と腸 44(5):843-854, 2009.
 
6) 小林清典,他:小腸悪性リンパ腫の診断臨床像と形態学的所見の特徴.胃と腸 41(3):304-314, 2006.
 
7) 中村昌太郎,他:【Midgut診療の新展開】《小腸腫瘍性疾患診療の進歩》小腸悪性リンパ腫の診断と治療. Mod Physician 32(7):878-881, 2012.
 
8) Rohatiner A, et al:Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma Ann Oncol 5(5):397-400, 1994.
PubMed
9) Swerdlow S C, et al:World Health Organization classhication of tumours:Pathology and genetics of tumours of haematopoietic and Lymphoid Tissues. 4th ed. IARC, Lyon, 2008.
 
10) 中村昌太郎:悪性リンパ腫, IPSID. 小腸疾患の臨床(八尾恒良,他編),医学書院東京, 2004.
 
11) 鶴丸大介,他:【小腸癌の診断と治療】小腸腫瘍の放射線診断.癌と化学療法 37(8):1450-1453, 2010.
 
12) 伊豆津宏二:【リンパ系腫瘍:診断と治療の進歩】トピックス リンパ系腫瘍の基本的事項画像診断.日内会誌 100(7):1794-1800, 2011.
 
13) Yamamoto S, et al:Gastrointestinal follicular lymphoma:review of the literature. J Gastroenterol 45(4):370-388, 2010.
PubMed
P.104 掲載の参考文献
1) 菊池昌弘:特異な組織像を呈するリンパ節炎について.日血会誌 35:119-120, 1972.
 
2) 藤本吉秀,他:頸部の亜急性壊死性リンパ節炎-新しい病態の提唱-.内科30:920-927, 1972.
 
3) Kucukardali Y, et al:Kikuchi's histiocytic necrotizing lymphadenitis:Kikuchi-Fujimoto Disease:analysis of 244 cases. Clin Rheumatol 26:50-54, 2007.
 
4) Song J Y, et al:Clinical outcome and predictive factors of recurrence among patients with Kikuchi's disease. Int J Infect Dis 13:322-326, 2009.
 
5) 山下泰治,他:抗核抗体高値が持続し短期間に無菌性髄膜炎を反復した亜急性壊死性リンパ節炎の 1 例.臨神経50:728-731, 2010.
 
6) Seong M G, et al:Clinicopathological review of immunohistochemically defined Kikuchi-Fujimoto disease-including some interesting cases. Clin Rheumatol 31:1463-1469, 2012.
 
7) Atwater A R, et al:Kikuchi's disease:Case report and systematic review of cutaneous and histopathologic presentations. J Am Acad Dermatol 59:130-136, 2008.
 
8) Mauleon C, et al:Kikuchi disease with skin lesions mimicking lupus erythematosus, J Dermatol Case Rep 3:82-85, 2012.
PubMed
9) Sato Y, et al:Histiocytic necrotizing lymphadenitis (Kikuchi's disease) with aseptic meningitis. J Neurol Sci 163:187-191, 1999.
 
10) Garcia-Zamallca A, et al:Bilateral pleural effusion and intestinal lung disease as unusual manifestations of kikuchi-fujimoto disease:case report and literature review. BMC Pulm Med 10:54, 2010.
 
11) Vijayaraghavan R, et al:Kikuchi-Fujimoto's involving mesenteric nodes:a report and review of literature. BMJ Case Rep 2011.
 
12) Monaco S E, et al:Benign non-infectious causes of lymphadenopathy;a review of cytomorphology and differential diagnosis. Diag Cytopathol 40:925-938, 2012.
 
13) Tsujikawa T, et al:Kikuchi-Fujimoto Disease PET/CT assessment of a rare cause of cervical lymphadenopathy. Clin Nucl Med 36:661-664, 2011.
PubMed
14) Lo W C, et al:Ultrasonographic differentiation between Kikuchi's disease and lymphoma in patients with cervical lymphadenopathy. Eur J Radiol 81:1817-1820, 2012.
 
15) Tsukahara M, et al:Cat scratch disease in Japan. Infect Chemother 8:321-325, 2002.
PubMed
16) BenAmi R, et al:Cat-scratch disease in elderly patients. Clin Infect Dis 41:969-971, 2005.
PubMed
17) Rosai J, et al:Sinus histiocytosis with massive lymphadenopathy:a newly recognized benign clinicopathological entity. Arch Pathol 87(1):63-70, 1969.
PubMed
18) Foucar E, et al:Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease):review of the entity. Semin Diagn Pathol 7(1):19-73, 1990.
 

第4章 管理・治療

P.112 掲載の参考文献
1) Lok A S, et al:Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188, 1991.
PubMed
2) Umemura T, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-e56, 2008.
PubMed
3) 坪内博仁, 他:免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告.肝臓50:38-42, 2009.
 
4) Oketani M, et al:Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42:627-636, 2012.
PubMed
5) Rehermann B, et al:The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108, 1996.
PubMed
6) Kusumoto S, et al:Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23, 2009.
PubMed
7) Yeo W, et al:Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009.
PubMed
8) Lau G K, et al:Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749, 2003.
PubMed
9) Yeo W, et al:Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000.
PubMed
10) Yeo W, et al:Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934, 2004.
PubMed
11) Lau G K, et al:High hepatitis B virus(HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99:2324-2330, 2002.
PubMed
12) Hui C K, et al:Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006.
PubMed
13) Cheng A L, et al:Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320-1328, 2003.
PubMed
14) Dhedin N, et al:Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation:a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66:616-619, 1998.
PubMed
15) Locasciulli A, et al:Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus(HBV)/hepatitis C virus(HCV) positive recipients:a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31:295-300, 2003.
 
16) Dervite I, et al:Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69, 2001.
 
17) Kusumoto S, et al:Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 46:9-16, 2011.
PubMed
18) Oshima K, et al:Reverse seroconversion of hepatitis B virus after alogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Hematology 14:73-75, 2009.
 
19) Ritchie D, et al:Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy:a case series report. Haematologica 94:1618-1622, 2009.
PubMed
20) Nakano N, et al:Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res 2013.(in press)
 
P.120 掲載の参考文献
1) 一般社団法人日本癌治療学会/編:制吐剤適正使用ガイドライン2010年5月【第1版】. 金原出版株式会社, 東京, 2010.
 
2) NCCN Clinical Practice Guideline in Oncology-Antiemesis-ver.4, 2009.
 
3) Perugia International Cancer Conference VH 2006, MASCC-Antiemetic Guideline-2008.
 
4) ASCO Guideline for Antiemetics in Oncology:Update 2006.
PubMed
5) Hesketh P J, et al:The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting:amultinational, randomized, double blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protcol 052 Study Group. J Clin Oncol 21 (22):4112-4119, 2003.
 
6) Schmoll H J, et al:Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000-1006, 2006.
PubMed
7) Koo W H, et al:Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7(1):71-74, 1996.
PubMed
8) de Wit R, et al:Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 85(8):1099-1101, 2001.
PubMed
9) Musso M, et al:Palonosetron (Aloxi(R)) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 17(2):205-209, 2009.
 
10) Malik I A, et al:Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18(2):170-175, 1995.
PubMed
11) Depre M, et al:Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 61(5-6):341-346, 2005.
 
12) McCrea J B, et al:Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylpredonisolone. Clin Pharmacol Ther 74(1):17-24, 2003.
 
13) Teunissen S C, et al:Symptom prevalence in patients with incurable cancer:A systematic review. J pain Symptom Manage 34(1):94-104, 2007.
 
14) NCCN Clinical Practice Guideline in Oncology ver.2, 2012.
 
15) Grunberg S M, et al:Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261-2268, 2004.
PubMed
P.127 掲載の参考文献
1) Swerdlow S H, et al:WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France, 2008.
 
2) Lister T A, et al:Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989.
PubMed
3) Rohatiner A, et al:Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma Ann Oncol 5:397-400, 1994.
PubMed
4) The International Non-Hodgkin's Lymphoma Prognostic Factors Project:A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med 329:987-994, 1993.
 
5) Shipp M A, et al:International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas:report of the jury. J Clin Oncol 17:423-439, 1999.
 
6) Solal-Celigny P, et al:Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004.
PubMed
7) Federico M, et al:Follicular lymphoma international prognostic index 2:a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009.
PubMed
8) Hasenclever D, et al:A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998.
PubMed
9) Salles G, et al:Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy(PRIMA):a phase 3, randomised controlled trial. Lancet 377:42-51, 2011.
 
P.136 掲載の参考文献
1) Brice P, et al:Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa:arandomized study from the Groupe d'Etude des Lymphomes Foliculaires. Groupe d'Etude des Lymphomes de PAdulte. J Clin Oncol 15(3):1110-1117, 1997.
PubMed
2) Colombat P, et al:Rituximab(anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation. Blood 97(1):101-106, 2001.
PubMed
3) Czuczman M S, et al:Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up. J Clin Oncol 22(23):4711-4716, 2004.
PubMed
4) Hiddemann W, et al:Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725-3732, 2005.
 
5) Marcus R, et al:Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579-4586, 2008.
PubMed
6) Federico M, et al:R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma:Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31(12):1506-1513, 2013.
 
7) Rummel M J, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013.(Epub 2013/02/26)
 
8) Tobinai K, et al:Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 24(1):174-180, 2006.
PubMed
9) Tobinai K, et al:Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci 100(10):1951-1956, 2009.
PubMed
10) Ogura M, et al:Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas:results of a Japanese phase II study. Int J Hematol 80(3):267-277, 2004.
 
11) Nagai H, et al:Cladribine combined with rituximab(R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Eur J Haematol 86(2):117-123, 2011.
PubMed
12) Friedberg J W, et al:Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma:results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204-210, 2008.
PubMed
13) Ohmachi K, et al:Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059-2064, 2010.
 
14) Robinson K S, et al:Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26(27):4473-4479, 2008.
PubMed
15) Tobinai K, et al:Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100(1):158-164, 2009.
 
16) Witzig T E, et al:Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 britumomab tiuxetan. Cancer 109(9):1804-1810, 2007.
PubMed
P.148 掲載の参考文献
1) Swerdlow S H, et al:editors. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2008.
 
2) Fisher R I, et al:Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328(14):1002-1006, 1993.
PubMed
3) Vose J M, et al:Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19(2):389-397, 2001.
 
4) Coiffier B, et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346(4):235-242, 2002.
PubMed
5) Feugier P, et al:Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d'Etude des Lymphomes de l'dulte. J Clin Oncol 23(18):4117-4126, 2005.
 
6) Habermann T M, et al Rituximab-CHOP versus CHOP alone or with maintenance rituximab m older patients with diffuse large B-cell lymphoma. Clin Oncol 24(19):3121-3127, 2006.
 
7) Pfreundschuh M, et al:Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105-116, 2008.
PubMed
8) Pfreundschuh M, et al:CHOP-like chemotherapy plus rituximab versus CHOP-hke chemotherapy alone in young Patients with good-prognosis diffuse large-B-cell lymphoma:arandomised controlled trial by the MabThera International Trial(MInT) Group. Lancet Oncol 7(5):379-391, 2006.
 
9) Gisselbrecht C, et al:R-ICE Versus R-DHAP in Relapsed patients with CD20Diffuuse Large B-Cell Lymphma(DLBCL) Followed by Stem Cell Transplantation and Maintenance Treament with Rituximab or Not:First Interim Analysis on 200 Patients. COPAL Study. Blood 110, ASH annual meeting abstract#517, 2007.
 
10) Crump M, et al:Gemcitabine, Dexamethasine, Ciplain(GDP) Compared to Dexamethasone, Cytarabine(DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas:Final Results of the Randomized Phase III NICIC CTG Sudy LY12 Blood 120, ASH annual meeting abstract #745, 2012.
 
11) Mounier N, et al Rituximab plus gemcitabine and oxaliplatin in refractory/relapsed patients with diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013(Epub ahead of print)
 
12) 金倉護監:血液診療エキスパート悪性リンパ腫, P276.中外医学社, 東京, 2010.
 
13) Ohmachi K, et al:Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 31(17):2103-2109, 2013.
 
14) Cheson B D:Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies, J Clin Oncol 28(21):3525-3530, 2010.
PubMed
15) Mossner E, et al:Increasing the efficacy of CD20 antibody therapy through the engineering of a new type H anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22):4393-4402, 2010.
 
16) Bowles J A, et al:Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108(8):2648-2654, 2006.
PubMed
P.157 掲載の参考文献
1) Vose J, et al:International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol 26(25):4124-4130,2008.
PubMed
2) Savage K J, et al:Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15(10):1467-1475,2004.
 
3) Schmitz N, et al:Treatment and prognosis of mature T-cell and NK-cell lymphoma:an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18):3418-3425,2010.
 
4) d'Amore F, et al:Up_front autologous stem-cell transplantation in peripheral T-cell lymphoma:NLG-T-01. J Clin Oncol 30(25):3093-3099,2012.
 
5) Zinzani P L, et al:Gemcitabine as single agent in pretreated T-cell lymphoma pa-tients:evaluation of the long-term outcome. Ann Oncol 21(4):860-863,2010.
 
6) Mahadevan D, et al:Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma:Southwest Oncology Group Study S0350. Cancer 119 (2):371-379,2013.
 
7) Pro B, et al:Brentuximab vedotin(SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma results of a phase II study. J Clin Oncol 30 (18):2190-2196,2012.
 
8) Olsen E A, et al:Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21):3109-3115,2007.
 
9) Damaj G, et al:Results from a prospective,open-label, phase ll trial of bendamustine inrefractory or relapsed T-cell lymphomas:the BENTLY trial J Clin Oncol 31(1):104-110,2013.
 
10) Chen A I, et al:Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphomec the Stanford experience. Biol Blood Marrow Transplant 14(7):741-747,2008.
PubMed
11) Le Gouill S, et al:Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults:a study by the Societe Francaise deGreffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26(14):2264-2271,2008.
PubMed
12) Dodero A, et al:Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas:long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect Leukemia 26(3):520-526,2012.
PubMed
13) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult Tcell leukaemia-lymphoma. A report fromthe Lymphoma Study Group(1984-87). Br J Haematol 79(3):428-437,1991.
 
14) Tsukasaki K, et al:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25(34):5458-5464,2007.
 
15) Ishida T, et al:Allogeneic hematopoieticstem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen:anationwide retrospective study. Blood 120(8):1734-1741,2012,
 
16) Kanda J, et al:Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia:a retrospective cohort study. Blood 119(9):2141-2148,2012.
PubMed
17) Itonaga H, et al:Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation:the Nagasaki Transplant Group experience. Blood 121(1):219-225,2013.
PubMed
18) Yamamoto K, et al:Phase I study of KW-0761,adefucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28(9):1591-1598,2010.
PubMed
19) Ishida T, et al:Defucosylated anti-CCR4 monoclonal antibody(KW-0761) for relapsed adult T-cell leukemia-lymphoma:a multicenter phase II study. J Clin Oncol 30(8):837-842,2012.
PubMed
P.167 掲載の参考文献
1) Chan J K C, et al:Extranodal NK/T-cell lymphoma, nasal type. In:World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (Jaffe E S, et al, eds). p285-288. IARC Press, Lyon, France, 2008.
 
2) Suzuki R:NK/T-cell lymphomas:pathobiology, prognosis and treatment paradigm. Curr Oncol Rep 14:395-402,2012.
PubMed
3) Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphoma in Japan:incidence of recently recognized entities. Pathol Int 50:692-702,2000.
 
4) Suzuki R, et al:Prognostic factors for mature natural killer (NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040,2010.
PubMed
5) Isobe Y, et al:T/NK cell type chronic active Epstein-Barr virus disease in adults:an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol 65:278-282,2012.
PubMed
6) Ohshima K, et al:CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes:a possible mechanism of immune evasion in chronic active EBV infection. Pathol Int 49:9-13,1999.
PubMed
7) Ohga S, et al:Dominant expression of interleukin-10 and transforming growth facter-b genes in activated T-cells of chronic active Epstein-Barr virus infection. J Med Virol 74:449-458,2004.
 
8) Yamaguchi M, et al:Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356,1995.
PubMed
9) Egashira M, et al:P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606,1999.
PubMed
10) Isobe Y, et al:Epstein-Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis. Br J Cancer 99:1816-1822,2008.
PubMed
11) Au W-Y, et al:Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:astudy of 136 cases from the international peripheral T-cell lymphoma project. Blood 113:3931-3937,2009.
 
12) Nagafuji K, et al:L-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74:447-450,2001.
PubMed
13) Ishida F, et al:Aggressive natural killer cell leukemia:therapeutic potential of L-asparaginase and allogeneic hematopoitic stem cell transplantation. Cancer Sci 103:1079-1083,2012.
 
14) Ando M,,et al:Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 130:860-868, 2005.
PubMed
15) Suto H, et al:Suppression of eIF4E expression by L-asparaginase. Acta Haematologica 123:215-219,2010.
PubMed
16) Kim G E, et al:Angiocentric lymphoma of the head and neck:patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63,2000.
PubMed
17) Isobe K, et al:Extranodal natural killer/T-cell lymphoma, nasal type. The significance of radiotherapeutic parameters. Cancer 106:609-615,2006.
PubMed
18) Yamaguchi M, et al:Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594-5600, 2009.
 
19) Yamaguchi M, et al:Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:an updated analysis of the Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 30:4044-4046,2012.
 
20) Kim S J, et al:Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage I E, nasal, extranodal NK/T-cell lymphoma:consortium for improving survival of lymphoma study. J Clin Oncol 27:6027-6032,2009.
 
21) Moon S H, et al:The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma:a comparison with conventional staging methods. J Nucl Med 54:1-6,2013.
PubMed
22) Suzuki R, et al:Prospective mesurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 118:6018-6022,2011.
 
23) Yamaguchi M, et al:Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type:NK-cell Tumor Study Group study. J Clin Oncol 29:4410-4416,2011.
 
24) Jaccard A, et al:Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117:1834-1839,2011.
PubMed
25) Tsukune Y, et al:Activity and safety of combination chemotherapy with methotrexate, ifosfamide, L-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies:a pilot study. Eur J Haematol 84:310-315, 2009.
PubMed
26) Truelove E, et al:The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 27:553-559,2013.
 
27) Ito Y, et al:Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extrandal NK/T-cell lymphoma, nasal type. Clin Cancer Res 18:4183-4190,2012.
PubMed
P.174 掲載の参考文献
1) Armitage J O:The history of autologoushematopoietic cell transplantation. In:Thomas' Hematopoietic Cell Transplantation (Appelbaum F R, et al, eds), p8-p14. Wiley-Blackwell, Oxford,2009.
 
2) Schriber J R, et al:Autologous transplantation for hematologic malignancies. In:Hematology:Basic Principles and Practice (Hoffman R, et al, eds), p1065-1618. Churchill Livingstone Elsevier, Philadelphia,2009
 
3) 日本造血細胞移植学会データセンター:日本造血細胞移植学平成24年度全国調査報書.日本造血細胞移植学会,名古屋,2013.
 
4) Shea T C, et al:Mobilization of autologous peripheral blood hematopoietic cells for cellular therapy. In:Thomas' Hematopoietic Cell Transplantation (Appelbaum F R, et al eds), p590-605. Wiley-Blackwell, Oxford,2009.
 
5) Holmberg L, et al:The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw 9(9):1060-1071,2011.
PubMed
6) Ayala E:Hematopoietic cell transplantation for B-cell lymphoma:an update. Cancer Control 19(3):175-186,2012.
 
7) Philip T, et al:Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540-1545,1995.
PubMed
8) Laport GG Changing role of stem cell transplantation in follicular lymphoma. Hematology Am Soc Hematol Educ Program 2012:417-425,2012
PubMed
9) Al Khabori M, et al:Autologous stem cell transplantation m follicular lymphoma:asystematic review and meta-analysis. J Natl Cancer Inst 104(1):18-28,2012.
 
10) Ladetto M, et al:Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventionale (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis:the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111(8):4004-4013,2008.
 
11) Le Gouill S, et al:Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96 (8):1128-1135,2011.
PubMed
12) Kumar A, et al:Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma:asystematic review and meta-analysis. J Natl Cancer Inst 101(2):100-106,2009.
 
13) Naumann-Winter F, et al:First-line tandem high-dose chemotherapy and autologous Stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiplemyeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 10:CD004626,2012
 
14) Wang L, et al:Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:a meta-analysis of randomized controlled trials. Hematol Oncol 30(2):57-61,2012.
PubMed
15)Faussner F, et al:Multiple myeloma:myeloablative therapy with autologous stem cell support versus chemotherapy:a meta-analysis. Anticancer Res 32(5):2103-2109, 2012.
PubMed
P.186 掲載の参考文献
1) Bierman p J, et al:Syngeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma:a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21:3744-3753,2003.
 
2) Butcher B W, et al:The graft-versus-lymphoma effect:clinical review and future opportunities. Bone Marrow Transplant 36:1-17,2005.
PubMed
3) van Besien K:Allogeneic stem cell transplantation in follicular lymphoma:recent progress and controversy. Hematology (Am Soc Hematol Educ Program):610-618,2009.
PubMed
4) van Besien K, et al:Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836,1998.
PubMed
5) van Besien K, et al:Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529,2003.
PubMed
6) Kim S W, et al:Myeloablative allogeneic hematopoietic stem cell transplantation fornon-Hodgkin lymphoma:a nationwide survey in Japan. Blood 108:382-389,2006.
 
7) Lazarus H M, et al:A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma:a report from the CIBMTR Biol Blood Marrow Transplant 16:35-45,
PubMed
8) Peniket AJ, et al:An EBMT registry matched study of allogeneic stem cell transplants for lymphoma:allogeneic transplantationls associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678,2003.
PubMed
9) Peggs K S, et al:Allogeneic transplantation or Hodgkin lymphoma. Br Haematol 143:468-480,2008.
 
10) Gajewski JL, et al Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. Clin Oncol 14:572-578,1996.
PubMed
11) Milpied N, et al:Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapse dodgkin's disease. European Group for Blood and Bone Marrow Transplantation. Clin Oncol 14:1291-1296,1996.
 
12) Izutsu K, et al:Unrelated bone marrow transplantation for non-Hodgkin lymphoma study from the Japan Marrow Donorrogram. Blood 103:1955-1960,2004.
PubMed
13) Avivi I, et al:Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma:an analysis from the lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 147:719-728,2009.
 
14) Hari P, et al:Allogeneic transplants in follicular lymphoma:higher risk of disease progression after reduced-intensity comparedo myeloablative conditioning. Biol Blood marrow Transplant 14:236-245,2008
PubMed
15) Sirvent A, et al:Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma:report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 16:78-85,
PubMed
16) Rezvani A R, et al:Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma:a multicentre experience. Br J Haematol 143:395-403,2008.
PubMed
17) Sureda A, et al Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma:an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455-462,2008.
PubMed
18) Sarina B, et al:Allogeneic transplantation improves the overall and progression-free survival of Hodgkm lymphoma patients relapsing after autologous transplantation:a retrospective study based on the time of HLA typing and donor availability. Blood 115:3671-3677,2010,
PubMed
19) Maris M B, et al:Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535-3542,2004.
PubMed
20) Horwitz S M:Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematology (Am Soc Hematol Educ Program):289-296,2008.
PubMed
21) Chakraverty R, et al:Allogeneic transplantation for lymphoma. Clin Oncol 29:1855-1863,2011.
PubMed
P.196 掲載の参考文献
1) Isaacson P:Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma Cancer 52(8):1410-1416,1983.
PubMed
2) Wotherspoon A C, et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342(8871):575-577,1993.
PubMed
3) Wotherspoon A C, et al:Helicobacter pylork associated gastritis and primary B-cell gastric lymphoma. Lancet 338(8776):1175-1176,1991.
PubMed
4) Du MQ et al:Gastric MALT lymphoma:from aetiology to treatment Lancet Oncol 3(2):97-104,2002.
PubMed
5) Starostik P, et al:Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways, Blood 99(1):3-9,2002.
 
6) Zulo A, et al:Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 8(2):105-110,2010,
 
7) Ruskone-Fourmestraux A, et al:EGIL Sonsensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60(6):747-758,2011.
 
8) Nakamura S, et al:Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori a multicentre cohort follow-up study of 420 patients in Japan. Gut 61(4):507-513,2012.
PubMed
9) Raderer M, et al:Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 55(5):616-618,2006.
PubMed
10) Akagi T, et al:A novel gene, MALTI at 18q21, is involved in t (11;18)(q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18(42):5785-5794,1999.
 
11) Dierlamm J, et al:The apoptosis inhibitorene API2 and a novel 18q gene, MLT, a recurrently rearranged in the t (11; 18) (q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93 (11):3601-3609,1999.
 
12) Morgan J A, et al:Breakpoints of the t(11;18) (q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 59(24):6205-6213,1999.
 
13) Wilis T G, et al:Bcl10 is involved in t (1;14) (p22;q32)of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96(1):35-45,1999.
 
14) Saito Y, et al:Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS one 7(11):e47396,2012.
PubMed
15) Suzuki H, et al:Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma:Updated Review of Clinical Outcomes and the Molecular Pathogenesis. Gut Liver 3(2):81-87,2009.
PubMed
16) Ye H, et al:High incidence of t(11;18) (q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 101(7):2547-2550,2003.
PubMed
17) Liu H, et al:T (11;18)is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 122(5):1286-1294,2002.
 
18) Nakamura T, et al:Clinicopathologic comparison between the APJ2-MALTI chimeric transcript-positive and-negative gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn J Cancer Res 93(6):677-684,2002.
 
19) Inagaki H, et al:Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 28(12):156-1567,2004.
 
20) Fukuhara N, et al:Chromosomal imbalances are associated with outcome of Helicobacter pylori eradication in t (11:18) (q21;q21) negative gastric mucosa-associated lymphoid tissue lymphomas. Genes Chromosomes Cancer 46(8):784-790,2007.
 
P.204 掲載の参考文献
1) Engert A, et al:Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652,2010.
 
2) Hutchings M:How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program 2012:322-327,2012.
PubMed
3) Eich H T, et al:Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma:final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206,2010.
 
4) Hasenclever D, et al:A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514,1998,
PubMed
5) Gallamini A, et al:Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma:A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752,2007.
 
6) Hoster E, et al:A new prognostic index (MIPI)for patients with advanced-stage mantle cell lymphoma Blood 111:558-565,2008.
PubMed
7) Howard O M, et al:Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:Molecular complete response are not predictive of progression-free survival. J Clin Oncol 20:1288-1294,2002.
 
8) Harel S, et al:Treatment of younger patients with mantle cell lymphoma. Semin Hematol 48(3):194-207,2011.
PubMed
9) Wang M, et al:Phase II study of yttrium-90-iburitumomab tiuxetan in patients with relapsed and refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-5218,2009.
PubMed
10) Ohmachi K, et al:Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9)2059-2064,2010.
 
11) Rummel M J, et al:Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389,2005.
 
12) Rummel M J, et al:Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210,2013.
PubMed
13) Ng A K, et al:Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108,2002.
PubMed
14) Aleman B M P, et al:Long-term cause specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439,2003.
 
15) MacDougall B K, et al:Second malignancies in non-Hodgkin's lymphoma. Cancer 48:1299-1301,1981.
PubMed
16) Travis LB, et al:Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85:1932-1937,1993.
PubMed
17) Pirani M, et al:Risk for second malignancies in non-Hodgkin's lymphoma survivors:a meta-analysis. Ann Oncol 22:1845-1858,2011
PubMed
P.213 掲載の参考文献
1) 畠清彦(編):がんの外来化学療法のマネジメント.医薬ジャーナル社,2005.
 
2) 横山雅大:外来化学療法と副作用対策血液腫瘍の外来化学療法はどこまで可能か?.腫瘍内科1:226-232,2007.
 
3) Jaffe E S, et al:World Health Organization Classification of Tumors. Tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon,2001.
 
4) 横山雅大:各がんの外来化学療法「悪性リンパ腫」.医のあゆみ222(13):1043,2007.
 
5) 湯地晃一郎:骨髄非破壊的前処置を用いた非血縁者間臍帯血移植(膀帯血ミニ移植)の医療経済解析.ファイザーヘルスリサーチ振興財団:研究助成,2005.
 
6) 李啓充:(連載)続アメリカ医療の光りと影第242回タイム誌史上最長記事に見る米国医療事情(1).週刊医学界新聞第3021号,2013.
 
7) 大阪府立成人病センターがん予防情報センター:「統計でみる大阪府のがん「がん医療水準均てん化」を探る」.p37-p50. 2011.
 

第5章 ガイドライン

P.222 掲載の参考文献
1) Hoppe R T, et al:Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:589-597,2012.
 
2) Tilly H, et al:Diffuse large B-cell lymphoma (DLBCL):ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Suppl 7):vii78-82.2012.
 
3) Flowers C R, et al:Antimicrobial Prophylaxis and Out patient Management of Fever and Neutropenia in Adults Treated for Malignancy:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 31:794-810,2013.
 
4) Schiffer C A, et al:Central Venous Catheter Care for the Patient With Cancer:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 31:1350-1370,2013.
 
5) Smith TJ, et al:2006 Update of Recommendations for the Use of White Blood Cell Growth Factors:An Evidence-Based Clinical Practice Guideline. J Clin Oncol 24:3187-3205,2006.
PubMed
6) Loren A W, et al:Fertility Preservation for patients With Cancer:American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013.(Epubhead of print)
 
7) Engert A, et al:Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial):a randomised,open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799,2012.
 
8) Dunleavy K, et al:Dose-adjusted EPOCH rituximabtherapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-1416,2013.
PubMed

書評

最近チェックした商品履歴

Loading...